LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Quatriga Low Osmo Peripheral

(alanine, arginine, glycine, histidine, isoleucine, leucine, lysine acetate, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, calcium chloride dihydrate, sodium glycerophosphate hydrate, magnesium sulfate heptahydrate, potassium chloride, sodium acetate trihydrate, zinc sulphate heptahydrate, glucose monohydrate, soya-bean oil refined, triglycerides medium chain, olive oil, refined, fish oil, rich in omega-3-acids)

SE/H/940/02/DC

This module reflects the scientific discussion for the approval of Quatriga Low Osmo Peripheral. The procedure was finalised on 2021-02-16. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, a marketing authorisation has been granted for Quatriga Low Osmo Peripheral, Emulsion for infusion.

The active substance is alanine, arginine, glycine, histidine, isoleucine, leucine, lysine acetate, methionine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine, valine, calcium chloride dihydrate, sodium glycerophosphate hydrate, magnesium sulfate heptahydrate, potassium chloride, sodium acetate trihydrate, zinc sulphate heptahydrate, glucose monohydrate, soya-bean oil refined, triglycerides medium chain, olive oil, refined, fish oil, rich in omega-3-acids. A comprehensive description of the indication and posology is given in the SmPC.

For recommendations to the marketing authorisation not falling under Article 21a/22a/22 of Directive 2001/83/EC and conditions to the marketing authorisation pursuant to Article 21a/22a/ 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

The application is an extension, new strength, of the previously authorised product Quatriga Perifer, emulsion for infusion marketed by Fresenius Kabi AB since 2007.

The application for Quatriga Low Osmo Peripheral, emulsion for infusion, is submitted according to Article 8(3) of Directive 2001/83/EC. The applicant, Fresenius Kabi AB applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and IT as concerned member states (CMS).

Potential similarity with orphan medicinal products
According to the application form and a check of the Community Register of orphan medicinal products there is no medicinal product designated as an orphan medicinal product for a condition relating to the indication proposed in this application.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

The present application concerns an extension application of a new strength to the previously authorised product Quatriga Perifer, emulsion for infusion. From a non-clinical perspective there are no changes to the products that would warrant new or additional data, and no such data of value for the assessment has been submitted.

IV. CLINICAL ASPECTS

Pharmacokinetics

The bioavailability of intravenously infused substances such as Quatriga Low Osmo Peripheral is 100%. No pharmacology studies have been performed with Quatriga Low Osmo Peripheral.

Pharmacodynamics

The pharmacodynamics of Quatriga Low Osmo Peripheral can be considered well characterised based on literature data on the individual components of Quatriga Low Osmo Peripheral, i.e. SMOFlipid 20%, Aminoven 10% with electrolytes, and glucose 11.8%.

Clinical efficacy

The clinical studies presented in the clinical overview have already been assessed in the previous procedures for SMOF range of the products. No new information has been provided regarding efficacy, and previous conclusions remain unchanged.

Taking into consideration that Quatriga Low Osmo Peripheral is a line extension of the SmofKabiven Peripheral, the efficacy claim for Quatriga Low Osmo Peripheral is based on the evidence available for the nutritional efficacy of its individual components. The applicant's proposal to use the evidence available for the efficacy of SmofKabiven Peripheral and its individual components to support the efficacy claim for the product is accepted.

Clinical safety

Quatriga Low Osmo Peripheral is composed of well-known components that are well-established in clinical practice for parenteral nutrition. There is extensive experience concerning safety of the individual components and their combination. The available post marketing experience from other SmofKabiven products is relevant to support the characterisation of safety for this line extension.

There is no reason to believe that the safety profile of the applied product should be different from other comparable marketed solutions.

Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Quatriga Low Osmo Peripheral.

Safety specification

Table- 1 Summary of Safety Concerns

Summary of Safety Concerns	
Important identified risks	• Metabolic/electrolytes abnormalities
Important potential risk	• Refeeding syndrome
Missing information	• Use in pregnant and lactating women • Use in newborns or infants below 2 years of age

Pharmacovigilance Plan

Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Risk minimisation measures

Routine risk minimisation is suggested and no additional risk minimisation activities are proposed by the applicant, which is endorsed.

Summary of the RMP

The submitted Risk Management Plan, version 1.2 signed 07 April 2017 is considered acceptable.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the RMS;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to SmofKabiven, SE/H/792/01/M. The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The benefit/risk ratio is considered positive and Quatriga Low Osmo Peripheral, Emulsion for infusion is recommended for approval.

List of recommendations not falling under Article 21a/22a/22 of Directive 2001/83/EC in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a/22a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

The decentralised procedure for Quatriga Low Osmo Peripheral, Emulsion for infusion was positively finalised on 2021-02-16.

LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected (Yes/No)	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se